vs
LivaNova PLC（LIVN）とTransMedics Group, Inc.（TMDX）の財務データ比較。上の社名をクリックして会社を切り替えられます
LivaNova PLCの直近四半期売上が大きい（$360.9M vs $160.8M、TransMedics Group, Inc.の約2.2倍）。TransMedics Group, Inc.の純利益率が高く（65.6% vs 8.6%、差は57.0%）。TransMedics Group, Inc.の前年同期比売上増加率が高い（32.2% vs 12.1%）。LivaNova PLCの直近四半期フリーキャッシュフローが多い（$50.2M vs $19.0M）。過去8四半期でTransMedics Group, Inc.の売上複合成長率が高い（28.8% vs 10.6%）
LivaNova PLCは医療機器メーカーで、イギリスに本社を置いています。心臓外科手術用機器と神経調整用機器の開発を主な事業とし、2015年に米国のサイバロニクス社とイタリアのソリン社が27億米ドルで合併して設立されました。現在はNASDAQに上場し、証券コードはLIVNです。
TransMedics Group, Inc.は臓器移植向けの革新的な医療技術を開発・販売する企業です。主力製品の臓器ケアシステムは輸送中のドナー臓器の生存性を維持し、心臓、肺、肝臓、腎臓移植の成功率向上に貢献し、北米、欧州、アジア太平洋地域の移植センターなどにサービスを提供しています。
LIVN vs TMDX — 直接比較
損益計算書 — Q4 2025 vs Q4 2025
| 指標 | | |
|---|---|---|
| 売上 | $360.9M | $160.8M |
| 純利益 | $30.9M | $105.4M |
| 粗利率 | 65.2% | 58.1% |
| 営業利益率 | 11.8% | 13.2% |
| 純利益率 | 8.6% | 65.6% |
| 売上前年比 | 12.1% | 32.2% |
| 純利益前年比 | -44.7% | 1436.9% |
| EPS（希薄化後） | $0.57 | $2.59 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $360.9M | $160.8M | ||
| Q3 25 | $357.8M | $143.8M | ||
| Q2 25 | $352.5M | $157.4M | ||
| Q1 25 | $316.9M | $143.5M | ||
| Q4 24 | $321.8M | $121.6M | ||
| Q3 24 | $318.1M | $108.8M | ||
| Q2 24 | $318.6M | $114.3M | ||
| Q1 24 | $294.9M | $96.8M |
| Q4 25 | $30.9M | $105.4M | ||
| Q3 25 | $26.8M | $24.3M | ||
| Q2 25 | $27.2M | $34.9M | ||
| Q1 25 | $-327.3M | $25.7M | ||
| Q4 24 | $55.9M | $6.9M | ||
| Q3 24 | $33.0M | $4.2M | ||
| Q2 24 | $16.3M | $12.2M | ||
| Q1 24 | $-41.9M | $12.2M |
| Q4 25 | 65.2% | 58.1% | ||
| Q3 25 | 68.4% | 58.8% | ||
| Q2 25 | 67.8% | 61.4% | ||
| Q1 25 | 69.7% | 61.5% | ||
| Q4 24 | 68.2% | 59.2% | ||
| Q3 24 | 70.8% | 55.9% | ||
| Q2 24 | 68.7% | 60.6% | ||
| Q1 24 | 70.3% | 61.9% |
| Q4 25 | 11.8% | 13.2% | ||
| Q3 25 | 15.1% | 16.2% | ||
| Q2 25 | 15.4% | 23.2% | ||
| Q1 25 | 15.3% | 19.1% | ||
| Q4 24 | 11.5% | 7.1% | ||
| Q3 24 | 11.2% | 3.6% | ||
| Q2 24 | 12.6% | 10.9% | ||
| Q1 24 | 5.5% | 12.8% |
| Q4 25 | 8.6% | 65.6% | ||
| Q3 25 | 7.5% | 16.9% | ||
| Q2 25 | 7.7% | 22.2% | ||
| Q1 25 | -103.3% | 17.9% | ||
| Q4 24 | 17.4% | 5.6% | ||
| Q3 24 | 10.4% | 3.9% | ||
| Q2 24 | 5.1% | 10.7% | ||
| Q1 24 | -14.2% | 12.6% |
| Q4 25 | $0.57 | $2.59 | ||
| Q3 25 | $0.49 | $0.66 | ||
| Q2 25 | $0.50 | $0.92 | ||
| Q1 25 | $-6.01 | $0.70 | ||
| Q4 24 | $1.04 | $0.19 | ||
| Q3 24 | $0.60 | $0.12 | ||
| Q2 24 | $0.30 | $0.35 | ||
| Q1 24 | $-0.78 | $0.35 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $635.6M | — |
| 総負債低いほど良い | $376.1M | — |
| 株主資本純資産 | $1.2B | $473.1M |
| 総資産 | $2.6B | $1.1B |
| 負債/資本比率低いほどレバレッジが低い | 0.31× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $635.6M | — | ||
| Q3 25 | $646.1M | — | ||
| Q2 25 | $593.6M | — | ||
| Q1 25 | $738.4M | — | ||
| Q4 24 | $428.9M | — | ||
| Q3 24 | $346.4M | $330.1M | ||
| Q2 24 | $329.2M | $362.8M | ||
| Q1 24 | $309.2M | $350.2M |
| Q4 25 | $376.1M | — | ||
| Q3 25 | $434.5M | — | ||
| Q2 25 | $430.6M | — | ||
| Q1 25 | $628.2M | — | ||
| Q4 24 | $627.0M | — | ||
| Q3 24 | $625.5M | — | ||
| Q2 24 | $624.5M | — | ||
| Q1 24 | $623.8M | — |
| Q4 25 | $1.2B | $473.1M | ||
| Q3 25 | $1.2B | $355.2M | ||
| Q2 25 | $1.1B | $318.1M | ||
| Q1 25 | $1.0B | $266.3M | ||
| Q4 24 | $1.3B | $228.6M | ||
| Q3 24 | $1.3B | $209.9M | ||
| Q2 24 | $1.2B | $189.9M | ||
| Q1 24 | $1.2B | $159.5M |
| Q4 25 | $2.6B | $1.1B | ||
| Q3 25 | $2.6B | $946.0M | ||
| Q2 25 | $2.5B | $890.5M | ||
| Q1 25 | $2.6B | $837.5M | ||
| Q4 24 | $2.5B | $804.1M | ||
| Q3 24 | $2.5B | $785.6M | ||
| Q2 24 | $2.5B | $758.6M | ||
| Q1 24 | $2.5B | $723.8M |
| Q4 25 | 0.31× | — | ||
| Q3 25 | 0.38× | — | ||
| Q2 25 | 0.38× | — | ||
| Q1 25 | 0.61× | — | ||
| Q4 24 | 0.47× | — | ||
| Q3 24 | 0.48× | — | ||
| Q2 24 | 0.50× | — | ||
| Q1 24 | 0.51× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $82.4M | $34.5M |
| フリーキャッシュフロー営業CF - 設備投資 | $50.2M | $19.0M |
| FCFマージンFCF / 売上 | 13.9% | 11.8% |
| 設備投資強度設備投資 / 売上 | 8.9% | 9.7% |
| キャッシュ転換率営業CF / 純利益 | 2.67× | 0.33× |
| 直近12ヶ月FCF直近4四半期 | $173.3M | $133.6M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $82.4M | $34.5M | ||
| Q3 25 | $85.1M | $69.6M | ||
| Q2 25 | $62.9M | $91.6M | ||
| Q1 25 | $24.0M | $-2.9M | ||
| Q4 24 | $78.7M | $19.7M | ||
| Q3 24 | $51.0M | $6.9M | ||
| Q2 24 | $43.4M | $25.7M | ||
| Q1 24 | $10.0M | $-3.4M |
| Q4 25 | $50.2M | $19.0M | ||
| Q3 25 | $62.2M | $61.9M | ||
| Q2 25 | $47.8M | $82.5M | ||
| Q1 25 | $13.2M | $-29.9M | ||
| Q4 24 | $68.3M | $6.1M | ||
| Q3 24 | $32.8M | $-41.3M | ||
| Q2 24 | $31.2M | $2.0M | ||
| Q1 24 | $3.6M | $-47.6M |
| Q4 25 | 13.9% | 11.8% | ||
| Q3 25 | 17.4% | 43.1% | ||
| Q2 25 | 13.6% | 52.4% | ||
| Q1 25 | 4.2% | -20.8% | ||
| Q4 24 | 21.2% | 5.0% | ||
| Q3 24 | 10.3% | -38.0% | ||
| Q2 24 | 9.8% | 1.7% | ||
| Q1 24 | 1.2% | -49.2% |
| Q4 25 | 8.9% | 9.7% | ||
| Q3 25 | 6.4% | 5.3% | ||
| Q2 25 | 4.3% | 5.8% | ||
| Q1 25 | 3.4% | 18.8% | ||
| Q4 24 | 3.2% | 11.2% | ||
| Q3 24 | 5.7% | 44.3% | ||
| Q2 24 | 3.8% | 20.8% | ||
| Q1 24 | 2.2% | 45.6% |
| Q4 25 | 2.67× | 0.33× | ||
| Q3 25 | 3.18× | 2.86× | ||
| Q2 25 | 2.32× | 2.62× | ||
| Q1 25 | — | -0.11× | ||
| Q4 24 | 1.41× | 2.87× | ||
| Q3 24 | 1.55× | 1.63× | ||
| Q2 24 | 2.65× | 2.11× | ||
| Q1 24 | — | -0.28× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
LIVN
| Other | $169.4M | 47% |
| Neuromodulation Segment | $119.7M | 33% |
| Cardiopulmonary Segment | $71.8M | 20% |
TMDX
| Liver Product | $127.0M | 79% |
| Heart Product | $26.0M | 16% |
| Other | $5.9M | 4% |
| Lung Product | $1.9M | 1% |
